Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced the upcoming presentation of data from recent Phase 2 clinical studies of Alvocidib at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30th thru June 3rd.
Help employers find you! Check out all the jobs and post your resume.
